Switch theme
Sign up to access all valuation multiples
Vaxcell-Bio Therapeutics is a bio-technology company engaged in the development of Cell-based and Protein-based Immunotherapeutics for the treatment of cancer.
2010
n/a
LTM Revenue n/a
LTM EBITDA n/a
$104M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Vaxcell-Bio has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Vaxcell-Bio achieved revenue of $1.3M and an EBITDA of -$6.1M.
Vaxcell-Bio expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Vaxcell-Bio valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $9K | $1.3M | XXX | XXX | XXX |
| Gross Profit | n/a | $5K | XXX | XXX | XXX |
| Gross Margin | NaN% | 0% | XXX | XXX | XXX |
| EBITDA | -$6.7M | -$6.1M | XXX | XXX | XXX |
| EBITDA Margin | -71635% | -470% | XXX | XXX | XXX |
| Net Profit | -$4.7M | -$7.0M | XXX | XXX | XXX |
| Net Margin | -49733% | -541% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Vaxcell-Bio's stock price is KRW 8090 (or $6).
Vaxcell-Bio has current market cap of KRW 186B (or $127M), and EV of KRW 152B (or $104M).
See Vaxcell-Bio trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $104M | $127M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Vaxcell-Bio has market cap of $127M and EV of $104M.
Vaxcell-Bio's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Vaxcell-Bio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Vaxcell-Bio and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $104M | XXX | XXX | XXX |
| EV/Revenue | 80.0x | XXX | XXX | XXX |
| EV/EBITDA | -17.0x | XXX | XXX | XXX |
| P/E | -17.5x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -10.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpVaxcell-Bio's NTM/LTM revenue growth is n/a
Vaxcell-Bio's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, Vaxcell-Bio's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Vaxcell-Bio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Vaxcell-Bio and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 13737% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -470% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -9% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 108% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 77% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 318% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 811% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| CSL | XXX | XXX | XXX | XXX | XXX | XXX |
| Imugene | XXX | XXX | XXX | XXX | XXX | XXX |
| Prescient Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| GSK India | XXX | XXX | XXX | XXX | XXX | XXX |
| AstraZeneca India | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Vaxcell-Bio acquired XXX companies to date.
Last acquisition by Vaxcell-Bio was XXXXXXXX, XXXXX XXXXX XXXXXX . Vaxcell-Bio acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Vaxcell-Bio founded? | Vaxcell-Bio was founded in 2010. |
| Where is Vaxcell-Bio headquartered? | Vaxcell-Bio is headquartered in South Korea. |
| Who is the CEO of Vaxcell-Bio? | Vaxcell-Bio's CEO is Mr. Je-jung Lee. |
| Is Vaxcell-Bio publicy listed? | Yes, Vaxcell-Bio is a public company listed on KRX. |
| What is the stock symbol of Vaxcell-Bio? | Vaxcell-Bio trades under 323990 ticker. |
| When did Vaxcell-Bio go public? | Vaxcell-Bio went public in 2020. |
| Who are competitors of Vaxcell-Bio? | Similar companies to Vaxcell-Bio include e.g. CSL, Imugene, Prescient Therapeutics, GSK India. |
| What is the current market cap of Vaxcell-Bio? | Vaxcell-Bio's current market cap is $127M |
| What is the current revenue growth of Vaxcell-Bio? | Vaxcell-Bio revenue growth between 2023 and 2024 was 13737%. |
| Is Vaxcell-Bio profitable? | Yes, Vaxcell-Bio is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
